Title: The increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance an

Objective: Increased serum ferritin levels, indicating increased body iron stores, have been found in overweight and obese PCOS women. This finding might result from the reduced menstrual losses secondary to from oligoor amenorrhea, or from the hyperinsulinism secondary to insulin resistance because insulin favors the intestinal absorption and the tissue deposition of iron. To explore which of these mechanisms is responsible for the increase in body iron stores in PCOS women, we have monitored the changes in serum ferritin levels during treatment with an antiandrogenic oral contraceptive or with an insulin sensitizer. Research Design and Methods: Thirty-four consecutive PCOS patients were randomized to an oral contraceptive containing 35 μg of ethinyl-estradiol plus 2 mg of cyproterone acetate (Diane Diario) or metformin (850 mg twice daily), and their serum ferritin levels were evaluated at baseline and after 12 and 24 weeks of treatment. Results: Despite the fact that treatment with Diane Diario restored regular menstrual cycles in all the patients, whereas metformin only did so in 50% of them, serum ferritin levels decreased at 12 and 24 weeks of treatment only with metformin, in association with a marked increase in insulin sensitivity. On the contrary, no changes in ferritin and insulin sensitivity were observed with Diane Diario. Conclusions: Our present results suggest that insulin resistance and hyperinsulinism, and not the reduced menstrual losses secondary to from oligoor amenorrhea, are responsible of the increased ferritin levels and body iron stores found in overweight and obese PCOS women. NLM Identifier NCT00428311 The polycystic ovary syndrome is a predominantly hyperandrogenic disorder (1) that affects 6 to 7% of premenopausal women (2-5). Aside from the hyperandrogenic features and ovarian dysfunction characteristic of the syndrome, obesity and insulin resistance are frequently associated with PCOS (6,7). We have reported previously (8) that overweight and obese women with PCOS have increased serum ferritin levels that do not relate to chronic inflammation, indicating that body iron stores are increased in these women in agreement with what has been published for other insulin resistant conditions (9). The increase in body iron stores might contribute to the insulin resistance and ß-cell dysfunction frequently found in PCOS patients (10), as has been previously proposed for insulin resistance (11), the metabolic syndrome (12), and type 2 diabetes (13,14). We hypothesized that genetic factors, the absence of a regular menstrual blood loss, or even the hyperinsulinemia resulting from insulin resistance, considering that insulin might stimulate intestinal iron absorption by up-regulating activity of hypoxia-inducible factor-1 alpha and down-regulating hepcidin expression (15,16), may have contributed to the increased body iron stores and serum ferritin levels observed in PCOS patients. Our recent results suggest that mutations in the hereditary hemochromatosis gene do not play a role in the increased body iron stores of PCOS patients (17). With the aim of evaluating which, of the two remaining etiologic mechanisms we initially suspected (absence of a regular menstrual blood loss or the hyperinsulinemia resulting from insulin resistance), is the major determinant of the increased iron stores found in overweight and obese PCOS patients, we have monitored serum ferritin levels in a group of PCOS patients randomly submitted to treatment with an antiandrogenic oral contraceptive – that regularizes menstrual dysfunction in all cases but does not improve insulin sensitivity – or to treatment with metformin – that improves insulin sensitivity but does not systematically regularizes menstrual cycles. As will be seen, our novel results strongly suggest that increased body iron stores in PCOS women are a consequence of insulin resistance and hyperinsulinemia that improves with insulin sensitization. Research Design and Methods Patients The present study derives from a more ample randomized controlled clinical trial addressing the effects of treatment with an antiandrogenic oral contraceptive compared with the insulin sensitizer metformin on classic and non-classic cardiovascular risk factors (ClinicalTrials.gov NLM Identifier NCT00428311). In brief, 34 consecutive PCOS patients were recruited (18). The diagnosis of PCOS was based on the presence of clinical and/or biochemical hyperandrogenism, oligoovulation and exclusion of secondary etiologies (19). The methods used to evaluate each particular criterion have been described in detail elsewhere (20). None of the patients had either a personal history of hypertension, diabetes mellitus or cardiovascular events, or received treatment with oral contraceptives, antiandrogens, insulin sensitizers or drugs that might interfere with blood pressure regulation, lipid profile or carbohydrate metabolism for the previous 6 months. Written informed consent was obtained from all the participants, and the study was approved by the local Ethics Committee and by the Spanish Drug Agency. After giving informed consent, patients were randomized to receive an antiandrogenic oral contraceptive containing 35 μg of ethinyl-estradiol plus 2 mg of cyproterone acetate (Diane Diario, Schering España S.A., Madrid, Spain) or 850 mg of metformin (Dianben, Merck Farma y Química S.A., Mollet del Vallés, Spain) daily for 24 weeks. Simple randomization was conducted using blocks of 10 sealed opaque envelopes assigning 5 patients to receive Diane Diario and 5 patients to receive metformin. Fifteen patients were allocated to treatment with Diane Diario and 19 were allocated to treatment with metformin. Treatment was started the first day of a spontaneous menstrual cycle or in women with amenorrhea, after excluding pregnancy by proper testing, and patients were instructed to maintain a diet containing 25-30 Kcal per kg of body weight and day and moderate physical activity throughout the trial. Metformin was started at a 425 mg twice daily dose during the first week to minimize gastrointestinal complaints. Patients were submitted to a complete evaluation at baseline and after 12 and 24 weeks of treatment for this and other studies that included anthropometric and laboratory measurements, a 75g oral glucose tolerance test with measurement of serum insulin and plasma glucose every 30 minutes for 2 hours, and several tests of cardiovascular performance. The 15 patients allocated to Diane Diario completed the study, whereas 7 of the 19 patients allocated to metformin discontinued metformin for different reasons (18). For the present study, serum ferritin and C-reactive protein (CRP) concentrations were measured by automated immunochemiluminescence (Immulite 2000 Ferritin and High Sensitivity CRP, Diagnostic Products Corporation, Los Angeles, CA) with lower limit of detection of 0.88 pmol/L and 0.1 mg/L respectively, and intraand interassay coefficients of variation below 10%. The technical characteristics of the assays employed for plasma glucose and serum hormone measurements have been described elsewhere (21-23). The composite insulin sensitivity index was calculated from the circulating glucose and insulin concentrations during the oral glucose tolerance test according to Matsuda and DeFronzo (24). Statistical analysis Data are shown as means ± SD unless otherwise stated. The sample size analysis for the clinical trial indicated adequate 0.80 powers with a total of 22 patients, as described in detail in the previous report of the study protocol (18). Normality of continuous variables was assessed by the Kolmogorov-Smirnov test and logarithmic transformation was applied as needed to ensure normality. The baseline characteristics of the patients randomized to receive Diane Diario or metformin were compared by unpaired t-test. During the study, the changes in continuous variables were analyzed by using a repeated-measures general lineal model including the arm of treatment as the between-subjects effect and the visit (baseline, 12 and 24 weeks) as the withinsubjects effect. To evaluate the differences in the response to each treatment, the interaction among the between-subjects and withinsubjects effect was calculated. The results obtained when considering only the patients completing the 3 visits of the protocol were also confirmed by intention to treat analysis assuming no changes in dependent variables at the missing visits with respect to the previous evaluation for patients discontinuing metformin. Categorical variables were analyzed by the χ, Fisher’s exact and McNemar’s test as appropriate. P < 0.05 was considered statistically significant. Analyses were performed using SPSS 10 for Macintosh (SPSS Inc, Chicago, Illinois). Results The complete baseline clinical, anthropometric, biochemical and hormone profiles of the PCOS patients randomized to treatment with Diane Diario or metformin, showing no differences between both groups, have been reported previously (18). Table 1 shows a selection of these variables, as well as the circulating ferritin, CRP and hemoglobin concentrations, hematocrit and mean erythrocyte corpuscular volume, and frequency of patients presenting with menstrual dysfunction at baseline, all of which were similar in the patients allocated to each arm of treatment. Of note, two of the 34 patients, of whom one was allocated to treatment with Diane Diario and another was allocated to metformin, had mean erythrocyte corpuscular volumes below 75 fL in the presence of a hematocrit value above 30%, suggesting a thalassemic trait (25). During treatment, serum ferritin levels decreased in the whole group of PCOS patients (Wilks’ λ = 0.741, F = 4.187, P = 0.028, Figure 1; intention to treat analysis: Wilks’ λ = 0.741, F = 5.412, P = 0.010), yet this finding was caused by the decrease observed only in patients treated with metformin, considering the statistically significant interact